市場調査レポート
商品コード
1123105
世界の肛門癌および大腸癌の世界市場:2022年~2028年Global Anal and Colorectal Cancer Market Research and Forecast 2022-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
世界の肛門癌および大腸癌の世界市場:2022年~2028年 |
出版日: 2022年07月20日
発行: Orion Market Research
ページ情報: 英文 130 Pages
納期: 2~3営業日
|
世界の肛門癌および大腸癌の市場規模は、予測期間中に2.8%のCAGRで拡大すると予測されています。肥満やタバコなどの生活習慣の乱れにより、肛門癌および大腸癌の有病率が高まっており、その治療に対する需要が市場成長の原動力となっています。
当レポートでは、世界の肛門癌および大腸癌市場について調査し、市場の概要とともに、治療タイプ別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。Global Anal and Colorectal Cancer Market Size, Share & Trends Analysis Report By Treatment (Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, and Immunotherapy), By End-User (Hospitals, Ambulatory Surgery Centers, and Cancer Research Centers) Forecast Period 2021-2027
The global anal and colorectal cancer market is anticipated to grow at a considerable CAGR of 2.8% during the forecast period. Anal and colorectal cancer is a malignant tumor that starts in the cells of the colon or the rectum while it takes place in the anus in the case of anal cancer. The rising prevalence of anal and colorectal cancer due to poor lifestyles such as obesity and tobacco consumption has created a demand for its treatment which in turn is driving the market growth. Colorectal cancer is the third most common malignancy and the fourth leading cause of cancer-related mortalities globally. As per the World Health Organization (WHO), in 2020, the number of colorectum cancer of mortality of male and female of all ages was around 935,173 across the globe, which is 9.4% of total mortalities. Additionally, the number of new colorectum cancer patients of both sexes of all ages in 2020 was around 1.9 million globally, which is 10.0% of new cancer cases.
As per the American Cancer Society, around 9,090 new cases of anal cancer are expected in the US in 2021, of which 6,070 in women and 3,020 in men. Besides, around 1,430 mortalities of anal cancer are expected in 2021. Apart from it, around 104,270 new cases of colon cancer and around 45,230 new cases of rectal cancer are expected in the US in 2021. Furthermore, the increasing geriatric population which is more prone to colorectal cancer is another factor driving the market growth. However, the high cost of anal and colorectal cancer treatment along with low awareness towards this type of cancer act as major restraints for the market growth. However, increasing healthcare expenditure, technological advancement for cancer treatment, and rising demand for anal and colorectal cancer treatment are expected to drive the market especially in developing countries.
Segmental Outlook
The global anal and colorectal cancer market is segmented based on treatment and end-user. Based on the treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Based on end-users the market is segmented into hospitals, ambulatory surgery centers, and cancer research centers. Hospitals held a major market share in 2020 based on end-user. The factors such as rising quality assessment in hospitals, growing colorectal cancer cases among individuals, and increasing demand for minimal complication rates in surgery of special colorectal cancer are anticipating to drive the growth of this market segment.
Global Anal and Colorectal Cancer Market Share by Treatment, 2020 (%)
Global Anal and Colorectal Cancer Market Share by Treatment
Surgery Segment holds the Significant share in the Market
The surgery segment held the highest share in 2020 and is also anticipated to grow during the forecast period. Surgery is done for the removal of the tumor and some surrounding healthy tissue during an operation. This is known as surgical resection. Surgery is the most common and widely used treatment for colorectal cancer. During surgery, a part of the healthy colon or rectum and nearby lymph nodes will be removed. When the colon cancer is very small then minimally invasive surgery will be done such as removing polyps during a colonoscopy (polypectomy), endoscopic mucosal resection, and laparoscopic surgery.
Regional Outlooks
The global anal and colorectal cancer market is further segmented based on geography including North America, Europe, Asia-Pacific, and the Rest of the World. North America has been predicted to dominate the global anal and colorectal cancer market. The high prevalence of anal & colorectal cancer cases in the US along with easy access of US citizens to its treatment due to the well-established health infrastructure of the region is anticipated to drive the growth of this regional market.
Global Anal and Colorectal Cancer Market Growth, by Region 2021-2027
Global Anal and Colorectal Cancer Market Growth, by Region
Asia-Pacific is projected to have a considerable share in the global anal and colorectal cancer market
Asia-Pacific is anticipated to hold a considerable market share in the global anal and colorectal cancer market. The rising geriatric population which is prone to cancer and increasing incidence and prevalence rate of anal and colorectal cancer are the factors that are growing the market demand in the region. As per the report of WHO, in 2020, in the Asia-Pacific region, around 569,186 incidences of colon cancer were recorded, which is 49.6% of total cases across the globe. The reason for more new cases of cancers and mortalities is having the largest population in the region. Besides, around 296,236 mortalities were recorded due to colon cancer in 2020, which was around 51.4%. Apart from this, the number of anal cancer patients in 2020 was 16,645, and mortalities were 8,120 in the region.
Market Players Outlook
The key players of the anal and colorectal cancer market Amgen Inc., Taiho Pharmaceutical Co., Ltd, Abbott Laboratories (Abbott Diagnostics), F.Hoffmann-La Roche Ltd, Quest Diagnostics Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2020, Genomictree Co. Ltd., a South Korea-based company, has announced that its US branch named Promis Diagnosis Inc., gained a fund of around $30.8 million this month. From August 2019, it has secured around $40.8 million in funds for the US-based branch.
The Report Covers
Market value data analysis of 2020 and forecast to 2027.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global anal and colorectal cancer market.
Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where in the market.